Serva Health Is Heading to ACCESS USA 2026

Advancing Patient Access, Affordability, and High-Touch Support

ACCESS USA 2026 arrives at a pivotal moment for U.S. market access and patient support. New affordability dynamics, evolving reimbursement and policy requirements, and rising operational expectations for hubs and patient assistance programs are reshaping what “excellent access” looks like for brands. This March, the access community will convene in Philadelphia for a gathering designed specifically to tackle those realities head-on. ACCESS USA 2026 takes place March 17–19, 2026, with Pre-Conference Workshops on March 16, 2026, at the Sheraton Philadelphia Downtown in Philadelphia, PA.

Serva Health will be there on the commercial side of our business, exhibiting at Booth #117. If you are responsible for access strategy, patient affordability, hub operations, rare disease commercialization, trade, or patient services performance, we look forward to connecting and comparing notes on what is working now and what needs to evolve next.

Why ACCESS USA matters now for commercial access leaders

ACCESS USA is built around a reality most commercial leaders feel daily: patient access is no longer a single handoff from payer approval to fill. It is an end-to-end operating model that must hold up under policy change, operational complexity, and heightened scrutiny, while still delivering a patient experience that supports starts and stays. ACCESS USA positions itself as a forum to accelerate access, partnerships and collaboration and bring stakeholders together for critical conversations to drive the future of patient access.

What makes ACCESS USA 2026 distinct

ACCESS USA is structured to unify three specialized conferences under one roof—anchoring broad access strategy while enabling deep dives into the operational and policy pressures shaping patient access and affordability today. Informa Connect describes ACCESS USA as the event that brings together PAP – Patient Assistance & Access Programs, Hub and Specialty Pharmacy Models East, and the Rare Disease Summit as one comprehensive experience. The program starts with pre-conference workshops on March 16, followed by three days of main sessions March 17–19.

A second differentiator is practical connectivity. ACCESS USA’s FAQs describe structured networking opportunities, including a welcome reception on March 16 and evening receptions in the exhibition hall on March 17 and March 18, plus roundtables and one-to-one meeting scheduling supported through the conference app. ACCESS USA also confirms a comprehensive exhibition featuring solution providers across the patient access ecosystem.

Finally, the venue and logistics are straightforward: the event is hosted at the Sheraton Philadelphia Downtown (201 N 17th St, Philadelphia, PA 19103).

The agenda themes that align with modern commercialization priorities

ACCESS USA’s three co-located events map closely to the “pressure points” commercial and market access executives are managing right now.

PAP – Patient Assistance & Access Programs highlights issues such as state-by-state policy impacts, IRA-related pressure and PBM tactics, Medicaid transformation, and prior authorization reform—topics explicitly previewed in the “what to expect” summary for PAP 2026. The PAP conference also positions itself as a place to explore AI’s impact on patient assistance program efficiency and to decode IRA implementation and strategic responses.

Hub and Specialty Pharmacy Models East emphasizes actionable operating improvements across hub operations and patient services. The Hub East page spotlights practical frameworks for scalable, tech-enabled hub programs, including implementing AI to improve patient experience, building data infrastructure, and personalizing patient journeys through predictive analytics. It also puts health policy squarely in focus, calling out areas such as IRA provisions (including copay smoothing and out-of-pocket caps), Medicare/Medicaid requirements, and 340B.

The Rare Disease Summit frames access and commercialization strategy through the unique constraints of small populations, high unmet need, and diagnostic complexity. It explicitly references the need to align cross-functional teams, design high-impact patient support programs, and leverage AI and advanced analytics to improve patient identification, engagement, and adherence. A major operational truth in rare disease is that patients often face prolonged time-to-diagnosis. For example, the NHS National Genomics Education Programme describes the “diagnostic odyssey” as an experience that takes, on average, 5.6 years. That delay has real implications for how brands design identification pathways, provider education, and patient support services. Making the Rare Disease Summit highly relevant for commercialization leaders beyond rare-only portfolios.

What Serva Health brings to ACCESS USA for commercial patient support programs

Serva Health’s commercial services are designed around a simple idea: commercial patient support is more effective when it combines trusted clinical engagement with purpose-built technology, operational flexibility, and program guardrails.

On the patient engagement side, our Patient Engagement Center as geared specifically to pharmaceutical industry needs and staffed 100% by experienced, registered nurses, supported by a virtual model designed for flexibility and compliance, including programs requiring clinical assessments, virtual injection training, and coordination with HCPs or payers. We also emphasizes a relationship-focused approach from awareness to access to education to adherence as part of delivering better patient experiences and outcomes.

This nurse-led model is meaningful in a commercial environment because nurses remain highly trusted by the public. The American Nurses Association notes that nurses have again been ranked the most trusted professionals in Gallup’s annual honesty and ethics poll, with 75% of Americans rating nurses’ honesty and ethical standards as “very high” or “high” in the most recent poll cited. When access and affordability are under pressure, credibility and empathy are not “soft” factors—they materially influence whether patients engage, complete steps, and persist.

Operationally, our commercial nurse call center highlights several principles that align directly with ACCESS USA themes: nurses identifying themselves as nurses from the initial contact, a relationship-based model that typically assigns one nurse per patient and supports routing calls back to the same nurse, commitment to scaling rapidly up or down, and training that emphasizes compliance, guardrails, and data security for commercialization program requirements.

ServaCore™ is positioned as a core differentiator for commercial programs. Its a proprietary, cloud-based, enterprise-level platform that is SOC 2 Type II audited, developed specifically for patient engagement programs for pharmaceutical manufacturers’ brands. Our technology capabilities that matter in hub and PSP environments: configurable portals with 360-degree views, bi-directional integration with third-party systems, tools supporting first-call resolution such as IVR and automated callback, and rapid deployment. Deployments are generally 75% faster than a typical patient support program. ServaCore™ offers modules for call routing (including routing patients to a dedicated nurse), omnichannel communications (SMS, email, live voice, live chat), and real-time dashboards and reporting.

Finally, Serva Health offers additional commercial services that is relevant for access leaders who need more than call-center execution. Serva supports for IT services (including unbranded and branded website hosting and email campaign management), program design collaboration for launches or transitions (including PDUFA launch support), reimbursement specialist services when prior authorization presents delays, and specialty pharmacy support.

Taken together, these capabilities intersect with ACCESS USA’s core discussions: affordability program pressures, evolving hub models, compliance, data infrastructure, and the move toward more personalized patient journeys supported by better technology and analytics.

Visit Serva Health at Booth #117

If you are attending ACCESS USA 2026, we invite you to visit Serva Health at Booth #117. You will find us in the exhibition environment that ACCESS USA describes as bringing together solution providers across the patient access ecosystem.

Whether your focus is optimizing a patient assistance program, modernizing hub operations, preparing for policy-driven workflow changes, improving adherence support, or aligning your patient services strategy with where access is heading next, ACCESS USA is designed for those exact conversations, and we are looking forward to having them in Philadelphia.